Clinical trial
A Phase II Randomized Trial of Camrelizumab With Stereotactic Body Radiotherapy Versus Camrelizumab Alone in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT04830267 is registered in ClinicalTrials.gov with Chongqing University Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Randomized Trial of Camrelizumab With Stereotactic Body Radiotherapy Versus Camrelizumab Alone in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
- Lead sponsor
- Chongqing University Cancer Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- March 1, 2021
- Completion date
- August 1, 2026
- Enrollment
- 39 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.